Niagen Bioscience, Inc 8-K, filed Nov 4, 2026
Niagen Bioscience, Inc. (NAGE)
8-K
2026-11-04
For: 2026-11-04
View Original
Added on
November 04, 2026
About this 8-K
Niagen Bioscience, Inc filed this 8-K on November 4, 2026.
Items reported
- Item 2.02: Financial results
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 4, 2026
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices, including zip code)
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
The | ||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On November 4, 2026, Niagen Bioscience, Inc. (the “Company”) issued a press release announcing its earnings for the quarter ended September 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1.
The information in this Item 2.02 and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, (the “Securities Act”) or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 7.01. Regulation FD Disclosure.
On November 4, 2026, the Company released a corporate presentation which it made available on its website. A copy of the corporate presentation is attached hereto as Exhibit 99.2.
The information in this Item 7.01 and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number | Description | |||||||
Press Release dated November 4, 2026 | ||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| NIAGEN BIOSCIENCE, INC. | ||||||||
Dated: November 4, 2026 | By: | /s/ OZAN PAMIR | ||||||
| Ozan Pamir | ||||||||
| Chief Financial Officer | ||||||||
| (principal financial officer and duly authorized on behalf of the registrant) | ||||||||
Niagen Bioscience, Inc. Reports Third Quarter 2026 Financial Results
Launched Niagen™ Plus Niagen™ Liquid At-Home Injections
Launched Niagen NanoCloud™, the first dermatologist-tested topical product
Launched “Don’t Get Old. Age Better.®,” a new brand campaign
Net sales of $27.2 million, including $23.3 million from Tru Niagen
Generated $2.6 million of operating cash flow
LOS ANGELES, CA - November 4, 2026 - Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced its operational updates and financial results for the third quarter of 2026.
Third Quarter 2026 Financial and Business Highlights
•Total net sales of $27.2 million, including $23.3 million from Tru Niagen®. Direct to consumer sales on the Company’s website grew by 13% year-over-year.
•Gross margin of 62.9%, which the Company believes reflects the strength of its operational foundation.
•Net loss of $1.2 million, with basic and diluted loss per share of $(0.01).
•Adjusted EBITDA, a non-GAAP measure, was positive at $0.5 million.
•Total cash provided by operations of $4.2 million during the nine months ended September 30, 2026, and $2.6 million in the three-month period.
•The Company ended the quarter with $69.5 million in cash and cash equivalents, as compared to $66.7 million in cash and cash equivalents for the period ended June 30, 2026.
•Launched the liquid, ready-to-inject Niagen™ At-Home Injection Kit, formulated with pharmaceutical grade Niagen nicotinamide riboside (NR) through the Niagen™ Plus telehealth platform.
•Launched Tru Niagen® Skincare, a permanent new category in the core Tru Niagen line. The inaugural product in this new category is Niagen NanoCloud™, the first dermatologist-tested topical product powered by Niagen NR.
•Launched “Don't Get Old. Age Better®,” a new brand campaign for the Niagen® brand and sub-brands Tru Niagen® and Niagen Plus™, featuring 11-time world champion surfer Kelly Slater and more than 20 partners, across sports, entertainment, and medicine.
•Announced a Start-Up Agreement with Mass General Brigham (MGB) to begin detailed planning for what is envisioned to be the largest and most comprehensive clinical trial of Niagen to date.
•NAD Pharmaceuticals engaged Red Sky Partners, a life sciences strategic advisory firm, to support the advancement of NB4168, the Company’s small molecule investigational drug candidate, targeting rare genetic diseases and aging-related disorders.
•Expanded access to Tru Niagen by launching on Walmart.com and diversified the e-commerce marketplace presence and expanded retail footprint by launching at nearly 300 GNC and Sam’s Club locations across 44 states combined.
•Announced the publication of a new peer-reviewed analysis of past clinical studies in Aging Cell examining the effects of Niagen® supplementation was associated with reduced muscle epigenetic age acceleration measured by the Muscle Epigenetic Age Test (MEAT) clock.
“During the third quarter, we navigated near-term commercial headwinds while continuing to generate positive adjusted EBITDA and $2.6 million in operating cash flow and make tangible progress across the Niagen platform,” said Rob Fried, Chief Executive Officer. “We advanced NB4168, expanded Tru Niagen distribution, established skincare as a permanent category, launched a more convenient ready-to-inject Niagen Plus product, and invested in brand awareness and long-term clinical research. As stated before, we view 2026 as an investment year, and believe the progress we are making across consumer health, ingredients, injectables, skincare, and pharmaceuticals provides a strong springboard for meaningful growth in 2027 and beyond.”
2026 Outlook and Strategic Priorities:
For the full year 2026, the Company expects direct website revenues to grow by 15% to 20% year-over-year and overall e-commerce to grow by approximately 5% year-over-year. The Company expects the performance of the remainder of its consumer business to offset the growth of the e-commerce business. The ingredient business is expected to be lower than the prior year, primarily due to decreased volume from key ingredient partners due to competitive market dynamics, although additional ingredient partners were added in Q3 2026 and more are expected to be added in the near term. The Company is planning to introduce a lower-cost NR salt form, patented by Niagen Bioscience, which is expected to reduce cost of goods sold and strengthen the ingredient business. The Company expects Niagen Plus growth and new skincare partnerships to become meaningful contributors beginning in 2027.
The Company believes 2026 is an important year of strategic investment and continues to expect operating expenses to increase as it invests across commercial, research and administrative functions to support these strategic priorities, while continuing to focus on disciplined capital allocation and positive cash flow from operations.
Investor Conference Call
A live webcast will be held Wednesday, November 4, 2026 at 4:30 p.m. Eastern Standard Time (1:30 p.m. Pacific Standard Time) to discuss Niagen Bioscience’s third-quarter financial results and provide a general business update.
To listen to the webcast, or to view the earnings press release and its accompanying financial exhibits, please visit the Investor Relations section of Niagen Bioscience’s website at https://investors.niagenbioscience.com. The toll-free dial-in information for this call is 1-833-461-5787 with Conference ID: 198389474. The webcast will be recorded, and will be available for replay via the website from 7:30 p.m. Eastern Standard Time on November 4, 2026.
Important Note on Forward-Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects,” “anticipates,” “intends,” “estimates,” “plans,” “potential,” “possible,” “probable,” “believes,” “seeks,” “may,” “will,” “should,” “could,” “predicts,” “projects,” “continues,” “would” or the negative of such terms or other similar expressions. Forward-looking statements include without limitation, statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the quotation from Niagen Bioscience’s Chief Executive Officer, statements related to the Company’s 2026 financial outlook including but not limited to net sales, gross margin, expenses, investment priorities, and commercialization efforts and statements regarding Niagen® and Niagen Plus clinical initiatives and statements attributable to management.
Risks that contribute to the uncertain nature of the forward-looking statements include: our relationships with major customers; a decline in general economic conditions nationally and internationally; the market and size of the vitamin, mineral and dietary supplement market and the intravenous market; decreased demand for our products and services; market acceptance of our products; the success of our brand campaign and other marketing investments; interruptions in our ability to sell products through third-party online marketplaces; the ability to protect our intellectual property rights; impact of any litigation or infringement actions brought against us; regulation of our advertising, marketing and sales practices by the FTC and state authorities; competition from other providers and products, including other supplements such as NMN; risks in product development; our ability to develop pharmaceutical business; the Company's therapeutic pipeline, including NB4168, preclinical and IND-enabling studies, and regulatory designations and development plans; inability to raise capital to fund continuing operations or new product development; changes in government regulation or regulatory priorities of government officials; the ability to complete customer transactions and capital raising transactions; inflationary conditions and adverse economic conditions; our history of operating losses; the growth and profitability of our product sales; our ability to maintain and grow sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; risks of conducting business in China; unanticipated developments in and risks related to the Company’s ability to secure adequate quantities of pharmaceutical-grade Niagen in a timely manner; the Company’s ability to obtain appropriate contracts and arrangements with U.S. FDA-registered 503B outsourcing facilities required to compound and distribute pharmaceutical-grade Niagen to clinics; the Company’s ability to remain on the U.S. FDA Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Category 1 list; the Company’s ability to maintain and enforce the Company’s existing intellectual property and obtain new patents; whether the potential benefits of NRC can be further supported; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other governmental authorities, including with respect to products seeking to compete in our market; mislabeling or other misleading marketing practices by competitors; economic and market instability, including as a result of tariffs or trade conflicts; and the risks and uncertainties associated with our business and financial condition in general, described in our filings with the Securities and Exchange Commission (SEC), including, without limitation, our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q as filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Niagen Bioscience undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
About Niagen Bioscience, Inc.:
Niagen Bioscience is a global bioscience company focused on healthy aging. The Company is a leader in research on NAD+ (nicotinamide adenine dinucleotide), an essential coenzyme that supports cellular metabolism and declines with age. Niagen Bioscience is the innovator of nicotinamide riboside (commonly referred to as “NR”), a patented NAD+ precursor commercialized as Niagen®, available in both food-grade and pharmaceutical-grade forms. Nicotinamide riboside and other NAD+ precursors are protected by Niagen Bioscience’s patent portfolio.
The Company markets its consumer supplement Tru Niagen® and develops and supplies Niagen® as a proprietary ingredient to partners across the health and wellness and pharmaceutical sectors. Niagen Bioscience is also advancing research and development of NAD+ precursor-based technologies for potential therapeutic applications. Follow us on X (formerly Twitter) @NiagenBio and Instagram @TruNiagen and @NiagenPlus and subscribe to our latest news via our website accessible at www.NiagenBioscience.com to which Niagen Bioscience regularly posts copies of its press releases as well as additional updates and financial information about the Company.
Contacts:
| Investor Relations | |||||
| KCSA Strategic Communications | |||||
| Valter Pinto, Managing Director | |||||
| 1 (212) 896-1254 | |||||
| Niagen@kcsa.com | |||||
| Media Relations | |||||
| Kendall Knysch | |||||
| Senior Director of Media Relations & Partnerships | |||||
| +1 (310) 405-5227 | |||||
| Kendall.Knysch@NiagenBio.com | |||||
Niagen Bioscience, Inc. and Subsidiaries
Unaudited Condensed Consolidated Statements of Operations
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
(In thousands, except per share data) | |||||||||||||||||||||||
| Sales, net | $ | 27,192 | $ | 33,986 | $ | 88,451 | $ | 95,584 | |||||||||||||||
| Cost of sales | 10,087 | 12,058 | 32,056 | 34,099 | |||||||||||||||||||
| Gross profit | 17,105 | 21,928 | 56,395 | 61,485 | |||||||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
| Sales and marketing | 8,713 | 8,768 | 28,518 | 25,092 | |||||||||||||||||||
| Research and development | 1,796 | 1,795 | 4,790 | 4,620 | |||||||||||||||||||
| General and administrative | 8,183 | 7,129 | 22,398 | 19,580 | |||||||||||||||||||
| Total operating expenses | 18,692 | 17,692 | 55,706 | 49,292 | |||||||||||||||||||
| Operating income (loss) | (1,587) | 4,236 | 689 | 12,193 | |||||||||||||||||||
| Nonoperating income: | |||||||||||||||||||||||
| Interest income, net | 414 | 564 | 1,161 | 1,575 | |||||||||||||||||||
Gain on sale of operating segment | — | — | 4,781 | — | |||||||||||||||||||
| Income (loss) before provision for income taxes | (1,173) | 4,800 | 6,631 | 13,768 | |||||||||||||||||||
| Provision for income taxes | — | 222 | 523 | 518 | |||||||||||||||||||
| Net income (loss) | $ | (1,173) | $ | 4,578 | $ | 6,108 | $ | 13,250 | |||||||||||||||
| Net income (loss) per share attributable to common stockholders: | |||||||||||||||||||||||
| Basic | $ | (0.01) | $ | 0.06 | $ | 0.08 | $ | 0.17 | |||||||||||||||
| Diluted | $ | (0.01) | $ | 0.05 | $ | 0.07 | $ | 0.15 | |||||||||||||||
| Weighted average common shares outstanding: | |||||||||||||||||||||||
| Basic | 79,149 | 79,779 | 79,460 | 78,953 | |||||||||||||||||||
| Diluted | 79,149 | 86,619 | 82,822 | 85,487 | |||||||||||||||||||
Niagen Bioscience, Inc. and Subsidiaries
Unaudited Condensed Consolidated Balance Sheets
(In thousands) | September 30, 2026 | December 31, 2025 | |||||||||
| Assets | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents, including restricted cash of $152 for both periods presented | $ | 69,509 | $ | 64,788 | |||||||
| Trade receivables, net of allowances of $103 and $147, respectively | 6,840 | 9,741 | |||||||||
| Inventories | 20,524 | 20,424 | |||||||||
| Assets held for sale | — | 541 | |||||||||
| Prepaid expenses and other assets | 3,342 | 1,312 | |||||||||
| Total current assets | 100,215 | 96,806 | |||||||||
| Leasehold improvements and equipment, net | 1,216 | 1,323 | |||||||||
| Intangible assets, net | 5,136 | 5,660 | |||||||||
| Right-of-use assets, net | 1,657 | 2,192 | |||||||||
| Other long-term assets | 470 | 425 | |||||||||
| Total assets | $ | 108,694 | $ | 106,406 | |||||||
| Liabilities and Stockholders' Equity | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 11,503 | $ | 10,796 | |||||||
| Accrued expenses | 3,933 | 7,722 | |||||||||
| Current maturities of operating lease obligations | 799 | 1,002 | |||||||||
| Current deferred consideration liability | 535 | — | |||||||||
| Customer deposits | 137 | 399 | |||||||||
| Total current liabilities | 16,907 | 19,919 | |||||||||
| Deferred revenue | 2,162 | 2,674 | |||||||||
| Operating lease obligations, less current maturities | 1,278 | 1,815 | |||||||||
| Deferred consideration liability, less current portion | 5,273 | 5,465 | |||||||||
Total stockholders’ equity | 83,074 | 76,533 | |||||||||
Total liabilities and stockholders’ equity | $ | 108,694 | $ | 106,406 | |||||||
Niagen Bioscience, Inc. and Subsidiaries
Unaudited Condensed Consolidated Statements of Cash Flows
| Nine Months Ended September 30, | |||||||||||
| (In thousands) | 2026 | 2025 | |||||||||
| Net cash provided by / (used in): | |||||||||||
| Operating activities | $ | 4,203 | $ | 12,825 | |||||||
| Investing activities | 5,101 | (191) | |||||||||
| Financing activities | (4,583) | 6,996 | |||||||||
| Net increase in cash and cash equivalents | 4,721 | 19,630 | |||||||||
| Cash and cash equivalents beginning of period | 64,788 | 44,660 | |||||||||
| Cash and cash equivalents at end of period | $ | 69,509 | $ | 64,290 | |||||||
Niagen Bioscience, Inc. and Subsidiaries
Unaudited Reconciliation of Non-GAAP Financial Measures
| Reconciliation of Net Income to Adjusted EBITDA | |||||||||||||||||||||||||||||
(In thousands) | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | ||||||||||||||||||||||||
| Net income, as reported | $ | (1,173) | $ | 963 | $ | 6,318 | $ | 4,132 | $ | 4,578 | |||||||||||||||||||
| Adjustments: | |||||||||||||||||||||||||||||
| Interest income, net | (414) | (372) | (375) | (552) | (564) | ||||||||||||||||||||||||
| Provision for income taxes | — | 106 | 417 | 292 | 222 | ||||||||||||||||||||||||
| Depreciation | 115 | 117 | 116 | 139 | 157 | ||||||||||||||||||||||||
| Amortization of intangibles | 175 | 174 | 175 | 60 | 38 | ||||||||||||||||||||||||
| Noncash lease expense | 183 | 179 | 173 | 169 | 164 | ||||||||||||||||||||||||
| Share-based compensation | 1,522 | 1,723 | 1,716 | 1,748 | 1,756 | ||||||||||||||||||||||||
| Severance and restructuring | 47 | 144 | 79 | 53 | 10 | ||||||||||||||||||||||||
| Gain on settlement of royalty obligation (1) | — | — | — | (1,983) | — | ||||||||||||||||||||||||
| Gain on sale of operating segment (2) | — | 3 | (4,784) | — | — | ||||||||||||||||||||||||
| Adjusted EBITDA | $ | 455 | $ | 3,037 | $ | 3,835 | $ | 4,058 | $ | 6,361 | |||||||||||||||||||
(1) Represents a gain related to the settlement of royalty obligations from a settlement agreement with Queen's University Belfast.
(2) Represents a gain related to the sale of the Company’s Analytical Reference Standards and Services operating segment.
Non-GAAP Financial Information:
To supplement Niagen Bioscience’s unaudited financial data presented in accordance with generally accepted accounting principles (GAAP), the Company has presented Adjusted EBITDA, a non-GAAP financial measure. Niagen Bioscience believes the presentation of this non-GAAP financial measure provides important supplemental information to management and investors and enhances the overall understanding of the Company’s historical and current financial operating performance. The Company believes disclosure of the non-GAAP financial measure has substance because the excluded expenses are infrequent in nature, are variable in nature or do not represent current cash expenditures. Further, such non-GAAP financial measure is among the indicators the Company uses as a basis for evaluating the Company’s financial performance as well as for planning and forecasting purposes. Accordingly, disclosure of this non-GAAP financial measure provides investors with the same information that management uses to understand the Company’s economic performance year-over-year.
Adjusted EBITDA is defined as net income before (a) interest, (b) provision for income taxes, (c) depreciation, (d) amortization, (e) non-cash share-based compensation costs, (f) severance and restructuring expense and (g) other infrequent items, including gains recognized related to the sale of an operating segment and a royalty settlement. While Niagen Bioscience believes that this non-GAAP financial measure provides useful supplemental information to investors, there are limitations associated with the use of such measure. This measure is not prepared in accordance with GAAP and may not be directly comparable to similarly titled measures of other companies due to potential differences in the method of calculation. Management compensates for these limitations by relying primarily on the Company’s GAAP results and by using Adjusted EBITDA only supplementally and by reviewing the reconciliation of the non-GAAP financial measure to its most comparable GAAP financial measure.
Non-GAAP financial measures are not prepared in accordance with, or an alternative for, generally accepted accounting principles in the United States. The Company’s non-GAAP financial measure is not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with the Company’s consolidated financial statements prepared in accordance with GAAP.
Earnings Presentation Third Quarter 2026 Nasdaq: NAGE | November 4, 2026
This presentation and other written or oral statements made from time to time by representatives of Niagen Bioscience contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements reflect the current view about future events. Statements that are not historical in nature, such as 2026 financial outlook, and which may be identified by the use of words like “expects,” “anticipates,” “intends,” “estimates,” “plans,” “potential,” “possible,” “probable,” “believes,” “seeks,” “may,” “will,” “should,” “could,” “predicts,” “projects,” “continue,” “would” or the negative of these terms and other words of similar meaning, are forward-looking statements. Such statements include, but are not limited to, statements contained in this presentation relating to our expected sales, cash flows, planned investments, and financial performance, business, business strategy, expansion, growth, key drivers (including cost savings and increased investments), products and services we offer and their impact on our performance or products and services we may offer in the future and the timing of their development, sales and marketing strategy and capital outlook. Forward-looking statements are based on management’s current expectations and assumptions regarding our business, the economy and other future conditions and are subject to inherent risks, uncertainties and changes of circumstances that are difficult to predict and may cause actual results to differ materially from those contemplated or expressed. We caution you therefore against relying on any of these forward-looking statements. These risks and uncertainties include those risk factors discussed in Part I, “Item 1A. Risk Factors” of our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “Commission”), and in subsequent filings with the Commission. Any forward-looking statements are qualified in their entirety by reference to the factors discussed in these filings with the Commission. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. Important factors that could cause actual results to differ materially from those in the forward looking statements include but are not limited to: our relationships with major customers; a decline in general economic conditions nationally and internationally; the market and size of the vitamin, mineral and dietary supplement market and the intravenous market; decreased demand for our products and services; market acceptance of our products; the success of our brand campaign and other marketing investments; interruptions in our ability to sell products through third-party online marketplaces; the ability to protect our intellectual property rights; impact of any litigation or infringement actions brought against us; regulation of our advertising, marketing and sales practices by the FTC and state authorities; competition from other providers and products, including other supplements such as NMN; risks in product development; our ability to develop pharmaceutical business; the Company's therapeutic pipeline, including NB4168, preclinical and IND-enabling studies, and regulatory designations and development plans; inability to raise capital to fund continuing operations or new product development; changes in government regulation or regulatory priorities of government officials; the ability to complete customer transactions and capital raising transactions; inflationary conditions and adverse economic conditions; our history of operating losses; the growth and profitability of our product sales; our ability to maintain and grow sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; risks of conducting business in China; unanticipated developments in and risks related to the Company’s ability to secure adequate quantities of pharmaceutical-grade Niagen in a timely manner; the Company’s ability to obtain appropriate contracts and arrangements with U.S. FDA-registered 503B outsourcing facilities required to compound and distribute pharmaceutical-grade Niagen to clinics; the Company’s ability to remain on the U.S. FDA Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Category 1 list; the Company’s ability to maintain and enforce the Company’s existing intellectual property and obtain new patents; whether the potential benefits of NRC can be further supported; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other governmental authorities, including with respect to products seeking to compete in our market; mislabeling or other misleading marketing practices by competitors; economic and market instability, including as a result of tariffs or trade conflicts; and the risks and uncertainties associated with our business and financial condition in general. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results. About Non-GAAP Financial Measures Niagen Bioscience’s non-GAAP financial measure, Adjusted EBITDA, is defined as net income before interest, provision for income taxes, depreciation, amortization, non-cash share-based compensation costs, severance and restructuring expense and other infrequent items, including gains recognized related to the sale of an operating segment and a royalty settlement. Niagen Bioscience used this non-GAAP measures when evaluating its financial results as well as for internal resource management, planning and forecasting purposes. This non-GAAP measure should not be viewed in isolation from or as a substitute for Niagen Bioscience’s financial results in accordance with GAAP. Reconciliation of this non-GAAP measure to the most directly comparable GAAP measure is attached to this presentation. Safe Harbor Statement FDA Disclaimer Statements made in this presentation have not been evaluated by the Food and Drug Administration. Niagen Bioscience products are not intended to diagnose, treat, cure, or prevent any disease. The statements in this presentation are for investor relations and educational purposes only and not intended for consumers or vendors. 2
Executing Long-Term Strategic Growth Initiatives Key strategic initiatives during Q3 2026. Consumer Products and Niagen Plus • Direct-to-consumer sales on the Company’s website grew by 13% year-over-year. • Launched the liquid, ready-to-inject Niagen Plus At-Home Injection Kit. • Launched Niagen NanoCloud™, the first dermatologist-tested topical product powered by Niagen NR. • Launched “Don't Get Old. Age Better®,” a new brand campaign for the Niagen® brand and sub-brands Tru Niagen® and Niagen Plus™, featuring 11-time world champion surfer Kelly Slater and more than 20 partners, across sports, entertainment, and medicine. • Launched on Walmart.com, GNC, and Sam’s Club locations. Drug Development • Engaged industry veterans from Red Sky Partners to support the advancement of NB4168, targeting rare genetic diseases and aging-related disorders. Research • Announced a Start-Up Agreement with Mass General Brigham (MGB) to begin detailed planning for what is envisioned to be the largest and most comprehensive clinical trial of Niagen to date. • Announced the publication of a new peer-reviewed analysis of past clinical studies, showing that Niagen® was associated with reduced muscle epigenetic age acceleration measured by the MEAT clock. 3
We are the global authority on NAD+ and healthy aging. We address aging at its root by unlocking the potential of NAD+, a vital coenzyme that declines with age. We developed Niagen®, the most efficient, high - quality NAD+ booster, and Tru Niagen®, the #1 NAD+ healthy aging supplement in the U.S. 1, as well as the Niagen Plus product portfolio for advanced delivery formats including infusions and injections. We have also developed Nanocloud skincare products containing Niagen and are developing therapies for rare genetic diseases. 1 Based on the top - selling dietary supplement brands by revenue per the largest U.S. e - commerce marketplace Niagen ® Bioscience Mission 4
A Platform Built on NAD+ Science NAD+ Declines by up to ~65% between the ages of 30 and 70 1 A vast body of research has established Nicotinamide Adenine Dinucleotide (NAD+) as a vital co - enzyme for cellular defense and repair NAD+ is important for energy production and is shown to help cells repair during recovery, sickness, and aging Niagen Bioscience’s patented NAD+ boosting ingredient, nicotinamide riboside, has been clinically demonstrated to increase NAD+ levels, while oral NAD+ itself has not been shown to elevate NAD+ levels 1 Massudi et al., 2012; Janssens et al., 2022 | Based on analysis of human skin and muscle tissue. Tissue NAD+ Decline Age 30 Age 70 DID YOU KNOW? 5
World’s Leading NAD+ Platform INJECTABLES & TELEHEALTH CORE BUSINESS SKINCARE PHARMACEUTICAL Injectables InfusionsBranded products Ingredient partners Branded topical products and upcoming partnerships with large skincare companies Drug development for treatment of rare genetic diseases 6
Clinical Studies on Oral Niagen ® Showed Positive Outcomes in Multiple Health Areas 2 years is the longest duration of supplementation Presterud et al., 2023 140 participants is the largest population studied in a clinical trial Conze et al., 2019 3000 mg is the highest dose with established safety Berven et al., 2023 Note: highlighted achievements in duration, participation and dosage only consider peer - reviewed, published studies. Status of clinical studies presented as of 10.28.2026 7
Charles Brenner, Ph.D. Professor of Metabolic Regulation Faculties of Medicine, Pharmacy, and Helsinki Institute of Life Science University of Helsinki World's Foremost Authority on NAD+ Metabolism Roger Kornberg, Ph.D. Professor of Structural Biology Stanford University Nobel Prize Winner, Chemistry, 2006 Rudolph Tanzi , Ph.D. Kennedy Professor of Neurology Harvard University Leading Alzheimer's Researcher, TIME 100 Most Influential 2015 Bruce German, Ph.D. Chairman of Food, Nutrition, & Health University of California, Davis Leader in Food, Nutrition, & Wellness Innovation Dr. Pinchas Hassy Cohen Dean & Professor of Gerontology, Medicine and Biological Sciences University of Southern California Aging expert with pioneering research and discoveries on mitochondria and novel microproteins Brunie H. Felding , Ph.D. Associate Professor of Molecular Medicine Scripps Research Institute Renowned Breast Cancer Researcher focused on NAD+ supplementation NOBEL PRIZE WINNER | CHEMISTRY Dr. Vilhelm (Will) Bohr, M.D., Ph.D., D.Sc. Professor in Genome Instability and Neurodegeneration, Department of Cellular and Molecular Medicine, University of Copenhagen. One of the world’s most published researchers on aging and neurodegenerative disease Scientific Advisory Board Guides Our Research -Driven Approach 8
Andrew Shao Ph.D SVP, Global Regulatory & Scientific Affairs Nutrition scientist and regulatory expert with extensive experience in dietary supplement research, global regulatory policy, and scientific affairs. Ozan Pamir Chief Financial Officer Finance executive with deep experience in life sciences, corporate strategy, and capital markets, bringing a strong background in financial leadership and investor relations. Carlos Lopez SVP, General Counsel Experienced legal executive in the dietary supplements and natural products industries, with a strong background in corporate governance, regulatory compliance, and commercial law. Michiko Kelley Chief Marketing Officer Global marketing executive with extensive experience in consumer and medical technology sectors, specializing in brand development, digital strategy, and international market expansion. Rob Fried Chief Executive Officer Seasoned entrepreneur and executive with decades of leadership experience spanning health and wellness, media, and technology, with a track record of building and scaling growth - oriented companies. Management Team 9
Financial Highlights 10
(1) See slide 15 for the non-GAAP reconciliation 62.9% gross profit margin Net loss of $(1.2) million or $(0.01) per share $0.5 million Positive Adjusted EBITDA(1) $69.5 million cash, no outstanding borrowings Third Quarter 2026 Highlights $27.2 million net sales $2.6 million Operating Cash Flow 11
(1) See slide 15 for the non-GAAP reconciliation. Net Sales $27.2M Tru Niagen $23.3M Gross Margin 62.9% Net Loss $(1.2)M Adj. EBITDA(1) $0.5M Cash & Liquidity Quarter-End Cash: $69.5M Borrowings: None Strong balance sheet supports our investment in long-term growth. Q3 2026: Investing for Long-Term Growth While Maintaining Financial Discipline 2026 Outlook Direct website growth of 15-20% E-commerce growth of 5%, remainder of the consumer business to offset the growth Niagen Plus and Skincare to become contributors in 2027 Cash flow from core business to fund strategic optionality in pharma, skincare, and telehealth Cash Generation $2.6M Cash from operations 12
2025 – 2026 Net Sales Summary ($ in millions) 2026 2025 Q1 Q2 Q3 Q1 Q2 Q3 Q4 FY Ecommerce 19.2 20.5 18.2 16.8 18.1 19.0 20.2 74.1 Watson’s & Other B2B 3.2 3.6 5.2 4.7 4.6 7.0 7.3 23.6 Total Tru Niagen 22.4 24.2 23.3 21.5 22.7 26.0 27.5 97.7 Food-grade Niagen 7.3 4.9 3.4 7.0 6.0 6.4 4.7 24.1 Pharmaceutical-grade Niagen 0.9 0.4 0.4 1.0 1.4 0.5 0.9 3.8 Total Niagen Ingredient 8.2 5.4 3.8 8.0 7.4 6.9 5.6 27.9 Niagen Related Revenues 30.6 29.5 27.1 29.5 30.1 32.9 33.1 125.6 Other Ingredients 0.4 0.0 0.0 0.2 0.2 0.3 0.0 0.7 Analytical Reference Standards & Services(1) 0.4 0.0 0.0 0.8 0.8 0.8 0.7 3.1 Corporate and Other(2) 0.1 0.2 0.1 0.0 0.0 0.0 0.0 0.0 Total Net Sales 31.5 29.8 27.2 30.5 31.1 34.0 33.8 129.4 Total Net Sales, Excluding Divested Segment 31.1 29.8 27.2 29.7 30.3 33.2 33.1 126.3 Tru Niagen as % of Total Net Sales 71 % 81 % 86 % 71 % 73 % 77 % 81 % 75 % Niagen Related Revenues as % of Total Net Sales 97 % 99 % 100 % 97 % 97 % 97 % 98 % 97 % YoY Growth Rate - Net Sales Total Company 3 % (4) % (20) % 38 % 37 % 33 % 16 % 30 % Niagen Related 4 % (2) % (18) % 37 % 38 % 33 % 18 % 31 % Total Tru Niagen 4 % 6 % (10) % 24 % 22 % 44 % 21 % 27 % (1) In February 2026, the Company divested its Analytical Reference Standards and Services operating segment. (2) Beginning March 2026 includes net sales from the transition services agreement (TSA) related to the divestiture of the operating segment. The TSA expired in August 2026. Note: Amounts presented in millions may not tie or sum to reported amounts in our 10-Q due to rounding. 13
Three Months Ended September 30, Nine Months Ended September 30, ($ in thousands) 2026 2025 2026 2025 Net Sales 27,192 33,986 88,451 95,584 Gross Profit % of Net Sales 17,105 62.9% 21,928 64.5% 56,395 63.8% 61,485 64.3% Sales and Marketing % of Net Sales 8,713 32.0% 8,768 25.8% 28,518 32.2% 25,092 26.3% Research and Development 1,796 1,795 4,790 4,620 General and Administrative (1) 8,183 7,129 22,398 19,580 Operating Income (Loss) (1,587) 4,236 689 12,193 Nonoperating - Gain on Sale of Operating Segment (2) — — 4,781 — Net Income (Loss) (1,173) 4,578 6,108 13,250 Adjusted EBITDA (3) 455 6,361 7,327 16,304 Key P&L Metrics (1) G&A during the nine months ended September 30, 2025 was reduced by a $1.3 million recovery of prior credit losses related to the Elysium Health legal settlement. (2) Reflects the gain on sale related to the divestiture of the analytical reference standards and services operating segment in February 2026. (3) See slide 15 for the non-GAAP reconciliation. 14
Adjusted EBITDA Summary Adjusted EBITDA remained positive at $0.5 million in Q3 2026 despite net loss during the quarter Reconciliation of Non-GAAP Financial Measures (In thousands) Three Months Ended FY 2025 Three Months Ended Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Net income (Loss), as reported $ 5,063 $ 3,609 $ 4,578 $ 4,132 $ 17,382 $ 6,318 $ 963 $ (1,173) Adjustments Interest income, net (459) (552) (564) (552) (2,127) (375) (372) (414) Provision for income taxes 168 128 222 292 810 417 106 — Depreciation 158 158 157 139 612 116 117 115 Amortization of intangibles 37 38 38 60 173 175 174 175 Noncash lease expense 173 159 164 169 665 173 179 183 Share-based compensation 1,075 1,488 1,756 1,748 6,067 1,716 1,723 1,522 Severance and restructuring 4 21 10 53 88 79 144 47 Gain on settlement of royalty obligation (1) — — — (1,983) (1,983) — — — Recovery of credit losses related to legal settlement (2) (1,325) — — — (1,325) — — — Gain on sale of operating segment (3) — — — — — (4,784) 3 — Adjusted EBITDA $ 4,894 $ 5,049 $ 6,361 $ 4,058 $ 20,362 $ 3,835 $ 3,037 $ 455 (1) Gain recognized related to the settlement of royalty obligations from an agreement with Queen's University Belfast. (2) The recovery of credit losses stems from the 2024 legal settlement with Elysium Health, LLC, paid in two installments, reversing a bad debt write-off from 2019. (3) Gain related to the sale of the Company’s Analytical Reference Standards and Services operating segment. 15
Quarterly Balance Sheet Highlights (in thousands) 9/30/25 12/31/25 3/31/26 6/30/26 9/30/26 Key Drivers Since Year-End (Q4 2025 vs Q3 2026) Cash $64,290 $64,788 $66,549 $66,740 $69,509 Up $4.7 million primarily driven by positive operating results and proceeds from the sale of the non-core business, partially offset by share repurchases Inventory 18,791 20,424 24,016 20,640 20,524 Remained well controlled as the Company balanced inventory with expected demand Trade Receivables 8,506 9,741 13,068 8,580 6,840 Down $2.9 million, reflecting a previously withheld receivables related to a dispute with a retail partner in Asia being released Accrued Liabilities 8,700 7,722 7,621 3,841 3,933 Down $3.8 million primarily due to payment of the liability settlement in Q1 2026 and normal changes in accrued compensation and other operating accruals Accounts Payable 12,742 10,796 13,277 9,439 11,503 Up $0.7 million due to normal operating activities and the timing of cash disbursements. Equity $70,676 $76,533 $82,330 $82,528 $83,074 Up $6.5 million driven by earnings, share-based compensation and stock option exercises, partially offset by share repurchases Financial strength supports disciplined investment, strategic flexibility, and long-term shareholder value creation. 16
$2.6M operating cash flow, $69.5M cash balance and no borrowings. Cash Flow Highlights Three Months Ended FY 2025 Three Months Ended Nine Months Ended September 30, 2026 (in thousands) 3/31/25 6/30/25 9/30/25 12/31/25 3/31/26 6/30/26 9/30/26 Net Income (Loss) $5,063 $3,609 $4,578 $4,132 $17,382 $6,318 $963 $(1,173) $6,108 Working Capital Changes 2,681 (4,399) (3,004) (3,669) (8,391) (5,017) (334) 1,937 (3,414) Cash Provided by / (Used for) Operations 7,883 1,250 3,692 679 13,504 (1,194) 2,772 2,625 4,203 Cash Provided by / (Used for) Investing (32) (135) (24) (101) (292) 5,245 (92) (52) 5,101 Cash Provided by / (Used for) Financing 3,105 (1) 3,743 (2) 148 (3) (80) (4) 6,916 (5) (2,290) (6) (2,489) (7) 196 (8) (4,583) (9) Net Increase in Cash $10,956 $4,858 $3,816 $498 $20,128 $1,761 $191 $2,769 $4,721 Ending Cash Balance $55,616 $60,474 $64,290 $64,788 $64,788 $66,549 $66,740 $69,509 $69,509 1. Includes $3.1 million in proceeds from the exercise of stock options. 2. Includes $3.7 million in proceeds from the exercise of stock options. 3. Includes $0.2 million in proceeds from the exercise of stock options. 4. Includes $0.2 million in proceeds from the exercise of stock options and ($0.3) million in repurchase of common stock 5. Includes $7.2 million in proceeds from the exercise of stock options and ($0.3) million in repurchase of common stock. 6. Includes $0.1 million in proceeds from the exercise of stock options and ($2.4) million in repurchase of common stock. 7. Includes $0.2 million in proceeds from the exercise of stock options, $0.1 million in proceeds from ESPP, and ($2.8) million in repurchase of common stock. 8. Includes $0.2 million in proceeds from the exercise of stock options. 9. Includes $0.5 million in proceeds from the exercise of stock options, $0.1 million in proceeds from ESPP, and ($5.1) million in repurchase of common stock. 17
Contact Info: Niagen Bioscience Investor Relations: KCSA Strategic Communications Valter Pinto, Managing Director T: +1 (212) 896-1254 Niagen@kcsa.com www.niagenbioscience.com Where to purchase Tru Niagen® TruNiagen.com Find Health Clinics Offering Niagen® Plus NiagenPlus.com 18